.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
QuintilesIMS
McKinsey
Accenture
Daiichi Sankyo
US Army
Covington
Deloitte
AstraZeneca
UBS

Generated: November 19, 2017

DrugPatentWatch Database Preview

Theravance Biopharma Company Profile

« Back to Dashboard

What is the competitive landscape for THERAVANCE BIOPHARMA, and what generic alternatives to THERAVANCE BIOPHARMA drugs are available?

THERAVANCE BIOPHARMA has one approved drug.

There are eleven US patents protecting THERAVANCE BIOPHARMA drugs.

There are one hundred and eighteen patent family members on THERAVANCE BIOPHARMA drugs in thirty-five countries and twelve supplementary protection certificates in eleven countries.

Summary for Theravance Biopharma

International Patents:118
US Patents:11
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► Subscribe ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► Subscribe ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Theravance Biopharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,903,070 Glycopeptide carboxy-saccharide derivatives► Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives► Subscribe
6,831,150 Reductive alkylation process► Subscribe
8,859,506Glycopeptide phosphonate derivatives► Subscribe
7,067,483Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin► Subscribe
7,157,554Glycopeptide carboxy-saccharide derivatives► Subscribe
7,265,086Glycopeptide carboxy-saccharide derivatives► Subscribe
8,541,375Glycopeptide phosphonate derivatives► Subscribe
6,887,976 Glycopeptide phosphonate derivatives► Subscribe
6,828,299 Polyhydroxy glycopeptide derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Theravance Biopharma Drugs

Country Document Number Estimated Expiration
China1871253► Subscribe
Ukraine75083► Subscribe
Portugal1292612► Subscribe
Canada2411590► Subscribe
Canada2726967► Subscribe
Japan3900491► Subscribe
TaiwanI305209► Subscribe
Iceland2303► Subscribe
Spain2271012► Subscribe
Cyprus1113773► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Theravance Biopharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011100062Germany► SubscribePRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
2012002Lithuania► SubscribePRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
2011 00033Denmark► Subscribe
C0051France► SubscribePRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
11/037Ireland► SubscribePRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
7Finland► Subscribe
2012002,C1292612Lithuania► SubscribePRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
C/GB11/056United Kingdom► SubscribePRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
908Luxembourg► Subscribe91908, EXPIRES: 20260501
/2011Austria► SubscribePRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
McKesson
US Department of Justice
McKinsey
Chinese Patent Office
Fuji
Johnson and Johnson
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot